Will NVIDIA Stock Bounce Back?
After the wild market moves during February and March, investors…
Sell
17
SINT Quote, Financials, Valuation and Earnings
Last price:
$1.80
Seasonality move
:
8%
Day range:
$1.81 - $1.91
52-week range:
$1.81 - $45.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.15x
P/B ratio:
1.19x
Volume:
80.7K
Avg. volume:
68.9K
1-year change:
-60.97%
Market cap:
$4.7M
Revenue:
$1.2M
EPS (TTM):
-$33.83
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SINT
SINTX Technologies
|
$550K | -$5.29 | 20.07% | -96.14% | $300.00 |
|
BLFS
BioLife Solutions
|
$22.2M | -$0.04 | -17.19% | -96.67% | $31.33 |
|
NMTC
NeuroOne Medical Technologies
|
-- | -- | 157.41% | -57.14% | -- |
|
NTRB
Nutriband
|
$710K | -$0.12 | -- | -- | $13.00 |
|
NVNO
enVVeno Medical
|
-- | -$0.34 | -- | -26.67% | $16.50 |
|
PLSE
Pulse Biosciences
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SINT
SINTX Technologies
|
$1.85 | $300.00 | $4.7M | -- | $0.00 | 0% | 1.15x |
|
BLFS
BioLife Solutions
|
$22.08 | $31.33 | $1B | -- | $0.00 | 0% | 11.66x |
|
NMTC
NeuroOne Medical Technologies
|
$0.55 | -- | $17M | -- | $0.00 | 0% | 2.74x |
|
NTRB
Nutriband
|
$4.96 | $13.00 | $55.1M | -- | $0.00 | 0% | 24.31x |
|
NVNO
enVVeno Medical
|
$2.25 | $16.50 | $39.4M | -- | $0.00 | 0% | 206.10x |
|
PLSE
Pulse Biosciences
|
$16.54 | -- | $1.1B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SINT
SINTX Technologies
|
0.82% | 0.462 | 0.68% | 1.91x |
|
BLFS
BioLife Solutions
|
4.37% | 2.243 | 1.31% | 3.48x |
|
NMTC
NeuroOne Medical Technologies
|
-- | -0.627 | -- | 2.23x |
|
NTRB
Nutriband
|
1.68% | 3.808 | 0.28% | 4.65x |
|
NVNO
enVVeno Medical
|
-- | 0.346 | -- | -- |
|
PLSE
Pulse Biosciences
|
-- | 4.760 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SINT
SINTX Technologies
|
$38K | -$1.6M | -146.19% | -148.9% | -875.52% | -$1.3M |
|
BLFS
BioLife Solutions
|
$8.3M | $1.4M | -5.7% | -6.05% | -147.28% | $583K |
|
NMTC
NeuroOne Medical Technologies
|
$1.9M | $1.7M | -238.93% | -238.93% | 64.45% | $183.6K |
|
NTRB
Nutriband
|
$191K | -$1.4M | -65.19% | -69.58% | -210.38% | -$1.1M |
|
NVNO
enVVeno Medical
|
-- | -$6.7M | -- | -- | -- | -$5.1M |
|
PLSE
Pulse Biosciences
|
-- | -$10.6M | -- | -- | -- | -$9.8M |
SINTX Technologies vs. Competitors
-
Which has Higher Returns SINT or BLFS?
BioLife Solutions has a net margin of -882.81% compared to SINTX Technologies's net margin of -363.87%. SINTX Technologies's return on equity of -148.9% beat BioLife Solutions's return on equity of -6.05%.
Company Gross Margin Earnings Per Share Invested Capital SINTSINTX Technologies19.79% -$1.26 $3.9M BLFSBioLife Solutions-241.56% $0.26 $364.8M -
What do Analysts Say About SINT or BLFS?
SINTX Technologies has a consensus price target of $300.00, signalling upside risk potential of 3683.78%. On the other hand BioLife Solutions has an analysts' consensus of $31.33 which suggests that it could grow by 41.91%. Given that SINTX Technologies has higher upside potential than BioLife Solutions, analysts believe SINTX Technologies is more attractive than BioLife Solutions.
Company Buy Ratings Hold Ratings Sell Ratings SINTSINTX Technologies0 1 0 BLFSBioLife Solutions7 0 0 -
Is SINT or BLFS More Risky?
SINTX Technologies has a beta of 1.124, which suggesting that the stock is 12.355% more volatile than S&P 500. In comparison BioLife Solutions has a beta of 1.933, suggesting its more volatile than the S&P 500 by 93.265%.
-
Which is a Better Dividend Stock SINT or BLFS?
SINTX Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioLife Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SINTX Technologies pays -- of its earnings as a dividend. BioLife Solutions pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SINT or BLFS?
SINTX Technologies quarterly revenues are $192K, which are larger than BioLife Solutions quarterly revenues of -$3.4M. SINTX Technologies's net income of -$1.7M is lower than BioLife Solutions's net income of $12.5M. Notably, SINTX Technologies's price-to-earnings ratio is -- while BioLife Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SINTX Technologies is 1.15x versus 11.66x for BioLife Solutions. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SINTSINTX Technologies1.15x -- $192K -$1.7M BLFSBioLife Solutions11.66x -- -$3.4M $12.5M
-
Which has Higher Returns SINT or NMTC?
NeuroOne Medical Technologies has a net margin of -882.81% compared to SINTX Technologies's net margin of 54.53%. SINTX Technologies's return on equity of -148.9% beat NeuroOne Medical Technologies's return on equity of -238.93%.
Company Gross Margin Earnings Per Share Invested Capital SINTSINTX Technologies19.79% -$1.26 $3.9M NMTCNeuroOne Medical Technologies58.85% $0.06 $2.9M -
What do Analysts Say About SINT or NMTC?
SINTX Technologies has a consensus price target of $300.00, signalling upside risk potential of 3683.78%. On the other hand NeuroOne Medical Technologies has an analysts' consensus of -- which suggests that it could grow by 262.19%. Given that SINTX Technologies has higher upside potential than NeuroOne Medical Technologies, analysts believe SINTX Technologies is more attractive than NeuroOne Medical Technologies.
Company Buy Ratings Hold Ratings Sell Ratings SINTSINTX Technologies0 1 0 NMTCNeuroOne Medical Technologies0 0 0 -
Is SINT or NMTC More Risky?
SINTX Technologies has a beta of 1.124, which suggesting that the stock is 12.355% more volatile than S&P 500. In comparison NeuroOne Medical Technologies has a beta of 0.692, suggesting its less volatile than the S&P 500 by 30.823%.
-
Which is a Better Dividend Stock SINT or NMTC?
SINTX Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroOne Medical Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SINTX Technologies pays -- of its earnings as a dividend. NeuroOne Medical Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SINT or NMTC?
SINTX Technologies quarterly revenues are $192K, which are smaller than NeuroOne Medical Technologies quarterly revenues of $3.3M. SINTX Technologies's net income of -$1.7M is lower than NeuroOne Medical Technologies's net income of $1.8M. Notably, SINTX Technologies's price-to-earnings ratio is -- while NeuroOne Medical Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SINTX Technologies is 1.15x versus 2.74x for NeuroOne Medical Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SINTSINTX Technologies1.15x -- $192K -$1.7M NMTCNeuroOne Medical Technologies2.74x -- $3.3M $1.8M
-
Which has Higher Returns SINT or NTRB?
Nutriband has a net margin of -882.81% compared to SINTX Technologies's net margin of -211%. SINTX Technologies's return on equity of -148.9% beat Nutriband's return on equity of -69.58%.
Company Gross Margin Earnings Per Share Invested Capital SINTSINTX Technologies19.79% -$1.26 $3.9M NTRBNutriband29.58% -$0.12 $11.4M -
What do Analysts Say About SINT or NTRB?
SINTX Technologies has a consensus price target of $300.00, signalling upside risk potential of 3683.78%. On the other hand Nutriband has an analysts' consensus of $13.00 which suggests that it could grow by 162.1%. Given that SINTX Technologies has higher upside potential than Nutriband, analysts believe SINTX Technologies is more attractive than Nutriband.
Company Buy Ratings Hold Ratings Sell Ratings SINTSINTX Technologies0 1 0 NTRBNutriband1 0 0 -
Is SINT or NTRB More Risky?
SINTX Technologies has a beta of 1.124, which suggesting that the stock is 12.355% more volatile than S&P 500. In comparison Nutriband has a beta of 1.049, suggesting its more volatile than the S&P 500 by 4.944%.
-
Which is a Better Dividend Stock SINT or NTRB?
SINTX Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SINTX Technologies pays -- of its earnings as a dividend. Nutriband pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SINT or NTRB?
SINTX Technologies quarterly revenues are $192K, which are smaller than Nutriband quarterly revenues of $645.8K. SINTX Technologies's net income of -$1.7M is lower than Nutriband's net income of -$1.4M. Notably, SINTX Technologies's price-to-earnings ratio is -- while Nutriband's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SINTX Technologies is 1.15x versus 24.31x for Nutriband. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SINTSINTX Technologies1.15x -- $192K -$1.7M NTRBNutriband24.31x -- $645.8K -$1.4M
-
Which has Higher Returns SINT or NVNO?
enVVeno Medical has a net margin of -882.81% compared to SINTX Technologies's net margin of --. SINTX Technologies's return on equity of -148.9% beat enVVeno Medical's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SINTSINTX Technologies19.79% -$1.26 $3.9M NVNOenVVeno Medical-- -$0.30 -- -
What do Analysts Say About SINT or NVNO?
SINTX Technologies has a consensus price target of $300.00, signalling upside risk potential of 3683.78%. On the other hand enVVeno Medical has an analysts' consensus of $16.50 which suggests that it could grow by 634.97%. Given that SINTX Technologies has higher upside potential than enVVeno Medical, analysts believe SINTX Technologies is more attractive than enVVeno Medical.
Company Buy Ratings Hold Ratings Sell Ratings SINTSINTX Technologies0 1 0 NVNOenVVeno Medical1 0 0 -
Is SINT or NVNO More Risky?
SINTX Technologies has a beta of 1.124, which suggesting that the stock is 12.355% more volatile than S&P 500. In comparison enVVeno Medical has a beta of 1.040, suggesting its more volatile than the S&P 500 by 3.991%.
-
Which is a Better Dividend Stock SINT or NVNO?
SINTX Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. enVVeno Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SINTX Technologies pays -- of its earnings as a dividend. enVVeno Medical pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SINT or NVNO?
SINTX Technologies quarterly revenues are $192K, which are larger than enVVeno Medical quarterly revenues of --. SINTX Technologies's net income of -$1.7M is higher than enVVeno Medical's net income of -$6.2M. Notably, SINTX Technologies's price-to-earnings ratio is -- while enVVeno Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SINTX Technologies is 1.15x versus 206.10x for enVVeno Medical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SINTSINTX Technologies1.15x -- $192K -$1.7M NVNOenVVeno Medical206.10x -- -- -$6.2M
-
Which has Higher Returns SINT or PLSE?
Pulse Biosciences has a net margin of -882.81% compared to SINTX Technologies's net margin of --. SINTX Technologies's return on equity of -148.9% beat Pulse Biosciences's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SINTSINTX Technologies19.79% -$1.26 $3.9M PLSEPulse Biosciences-- -$0.18 -- -
What do Analysts Say About SINT or PLSE?
SINTX Technologies has a consensus price target of $300.00, signalling upside risk potential of 3683.78%. On the other hand Pulse Biosciences has an analysts' consensus of -- which suggests that it could fall by -69.77%. Given that SINTX Technologies has higher upside potential than Pulse Biosciences, analysts believe SINTX Technologies is more attractive than Pulse Biosciences.
Company Buy Ratings Hold Ratings Sell Ratings SINTSINTX Technologies0 1 0 PLSEPulse Biosciences0 0 0 -
Is SINT or PLSE More Risky?
SINTX Technologies has a beta of 1.124, which suggesting that the stock is 12.355% more volatile than S&P 500. In comparison Pulse Biosciences has a beta of 1.874, suggesting its more volatile than the S&P 500 by 87.435%.
-
Which is a Better Dividend Stock SINT or PLSE?
SINTX Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pulse Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SINTX Technologies pays -- of its earnings as a dividend. Pulse Biosciences pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SINT or PLSE?
SINTX Technologies quarterly revenues are $192K, which are larger than Pulse Biosciences quarterly revenues of --. SINTX Technologies's net income of -$1.7M is higher than Pulse Biosciences's net income of -$10.1M. Notably, SINTX Technologies's price-to-earnings ratio is -- while Pulse Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SINTX Technologies is 1.15x versus -- for Pulse Biosciences. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SINTSINTX Technologies1.15x -- $192K -$1.7M PLSEPulse Biosciences-- -- -- -$10.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Energy Transfer a Good Dividend Stock to Buy Now?
Energy Transfer (NYSE:ET) offers an impressive yield, to say the…
Did the Market Bottom Already?
The past few weeks have been among the most volatile…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
78
BMA alert for Apr 15
Banco Macro SA [BMA] is down 2.47% over the past day.
Buy
72
BKTI alert for Apr 15
BK Technologies [BKTI] is up 2.01% over the past day.
Buy
71
GGAL alert for Apr 15
Grupo Financiero Galicia SA [GGAL] is down 2.98% over the past day.
